The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-387 Under Fed Condition

Inclusion criteria

• Healthy adults aged 19 to 55 years
• Females must be menopause or surgical infertility
• Signed informed consent form
• Other inclusion criteria, as defined in the protocol

Exclusion criteria

• History of clinically significant hepatic, renal, nervous, immune, respiratory, endocrine, hemato-oncology, cardiovascular systemic disease or psychosis disorder
• Clinical laboratory test values are outside the accepted normal range at Screening

• aspartate aminotransferase(AST), alanine aminotransferase(ALT) > 1.25 times the upper limit of the normal range
• Total Bilirubin > 1.5 times the upper limit of the normal range
• creatine phosphokinase(CPK) > 1.5 times the upper limit of the normal range
• estimated Glomerular Filtration Rate(eGFR, MDRD* formula) < 60 mL/min/1.73m2 (*MDRD: Modification of Diet in Renal Disease)
• Positive reaction on following tests: Hepatitis B, Hepatitis C, human immunodeficiency virus(HIV) and syphilis
• systolic blood pressure(SBP) ≥ 150 mmHg or < 90 mmHg, diastolic blood pressure(DBP) > 100 mmHg or < 50 mmHg
• Subject who smoke heavily or drink caffeine or alcohol continuously and who cannot discontinue smoking, caffeine or alcohol intake during hospitalization
• Participated in a clinical trial within 90 days prior to 1st IP dosing
• Not eligible to participate for the study at the discretion of Investigator
• Other exclusive inclusion criteria, as defined in the protocol